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Introduction
To overcome existing problems associated with drug delivery to articular tissues, we have explored the application of gene therapy to the treatment of RA and other joint pathologies. 1, 2 The development of effective gene delivery systems capable of secreting proteins with antiarthritic or therapeutic properties into the tissues of the joint space may provide an effective method for treating RA.
Initially, an ex vivo approach to gene delivery to the joint was tested. For this procedure, cells were surgically harvested from the synovial lining of the joint, cultured and transduced by a retroviral vector in vitro, and the genetically modified cells injected into the joint space to recolonize the synovium. 3, 4 Ex vivo delivery of the interleukin-1 receptor antagonist cDNA to the joints of rabbits with experimental arthritis was found to have significant therapeutic benefit. 5 More recently, a phase I clinical trial was implemented to evaluate the safety and feasibility of using ex vivo gene delivery in the treatment of RA. Results demonstrated expression of the transgene product that supported the initiation of a phase II clinical trial.
Although the ex vivo method has been shown to be an effective approach, the expense and labor associated with the procedure may hinder its application on a widespread scale. In an effort to devise a more practical strategy, several laboratories have been exploring the use of direct, in vivo gene delivery to the joint. [7] [8] [9] [10] [11] A number of viral and nonviral vectors have been found to deliver DNA to synovial cells efficiently. We have recently shown that direct intra-articular injection of adenoviral vectors encoding soluble receptors for interleukin-1 (IL-1) and tumor necrosis factor ␣ (TNF␣) were able to block effectively many of the pathologies associated with antigen-induced arthritis in rabbits. 12 While the first-generation adenovirus vectors used in these experiments are highly efficient at gene delivery to the synovium, transgene expression is transient. This may be due in part to expression of virally encoded proteins by cells infected by these first-generation vectors known to stimulate antiviral responses, leading to loss of transgene expression and immune rejection of virus infected cells.
The experiments conducted with adenoviral vectors indicate that therapeutic levels of protein can be expressed intra-articularly following direct in vivo gene delivery to joints. However, to make this approach viable it will be necessary to develop a gene delivery vehicle capable of persistent transgene expression with minimal side-effects. Furthermore, RA is an autoimmune disease involving a complex network of immune cells, inflammatory cytokines such as TNF␣ and IL-1, cellular recep-tors and effector molecules. It is likely that successful, persistent down-regulation of the autoimmune disease process will necessitate the simultaneous delivery of several gene products and complex regulatory signals for coordinated expression. To this end, we have been evaluating the utility of herpes simplex virus (HSV) as a vector for gene delivery to the synovium and joint tissues. Several features of this virus make it a potentially valuable gene-delivery vector for the treatment of RA. First, the relatively large approximately 152 kb genome enables the insertion of multiple therapeutic coding regions and regulatory domains. 13, 14 Second, HSV is also known to establish latency in neurons, which may allow for persistent expression of transgene products from the neurons innervating the target joint. Finally, preliminary studies with a first-generation vector have shown that HSV is highly infectious for synovial cells in culture and in experimental animals. 8 During infection with wild-type HSV, a viral tegument polypeptide, VP16, activates transcription of five immediate-early (IE) genes encoding infected cell polypeptide (ICP) 0, 4, 22, 27 and 47. 15, 16 Expression of these IE genes is essential for regulating the expression of subsequent early and late viral genes necessary for HSV replication. Initial replication deficient HSV-based vectors were constructed by mutagenesis of the ICP4 gene. 17, 18 Following production in ICP4 complementing cell lines, this vector proved to be highly efficient in the infection of a variety of cell types. However, when delivered to the joint space via intra-articular injection, the duration of transgene expression was limited, as infection with the vector proved to be cytotoxic and highly inflammatory. Recently we have constructed second-generation HSV vectors in which the ICP 4, 22 and 27 as well as UL41 genes have been inactivated. Studies by Krisky et al 19 have shown that this virus has a significantly reduced cytotoxicity both in vitro and in vivo. Thus, these vectors might represent improved vehicles for gene delivery to the joint. To examine this possibility we evaluated the ability of second-generation vectors to deliver a transgene and express a secretable gene product in normal and arthritic rabbit knee joints. In this article we demonstrate that the level and duration of transgene expression from secondgeneration vectors is significantly improved compared with first-generation HSV vectors such that biologically relevant levels of IL-1Ra can be delivered to block the onset of pathology in experimental arthritis in the rabbit knee.
Results
Initial studies by Nita et al 8 indicated that first-generation HSV vectors were efficient at transferring exogenous genes to the synovial lining of the joint, but also produced substantial inflammatory and cytotoxic effects following intra-articular delivery. Recently, second-generation HSV vectors have been created which are considerably less toxic than the first-generation vectors when tested in a number of cell types. 19 In order to determine if these vectors represent an improved gene delivery vehicle for intra-articular gene transfer, first-and second-generation vectors (termed S/0− and T/0, respectively) were created that carried identical expression cassettes composed of the cDNA encoding the human soluble p55, type I TNF † receptor fused to the C H 2 and C H 3 domains of the mouse IgG1 molecule (sTNFSR). Transcription of the TNFSR coding region was driven by the HSV ICP 0 immediate-early promoter ( Figure 1 ). Before use in vivo, expression of TNFSR protein from each of these vectors was demonstrated in vitro following infection of HIG-82 cells (MOI 3), a rabbit synovial fibroblast cell line (Figure 2a) . 20 ELISA measurements on supernatants from infected cultures demonstrated that cells transduced by either vector produced greater than 100 ng of soluble sTNFSR/10 6 cells/24 h. No appreciable TNFSRwas detected in uninfected cultures.
To compare the relative levels and duration of expression of the first-and second-generation vectors in vivo, three-fold increments of the S/0-TNFSR and T/0-TNFSR vectors were injected directly into knee joints of young New Zealand White rabbits. At 3 days after injection, the knees of the rabbits were lavaged with saline solution and the recovered fluids analyzed for TNFSR expression. As shown in Figure 2b , 3 days following injection of the second-generation vector, greater than 8 ng of soluble protein were detected in the synovial lavage fluid by ELISA. The S/0-TNFSR vector, however, failed to produce detectable levels of soluble p55 protein at this time-point. By 7 days after infection, sTNFSR expression in knees injected with T/0− based vector still persisted, but had decreased by approximately 60% (data not shown). No measurable expression was observed in any joints by day 14. Reinfection of these joints failed to produce significant levels of the transgene. These results are in agreement with earlier studies and indicate that the inactivation of the ICP 22 and ICP27 genes alters the HSV-based vector such that it is capable of prolonged intra-articular transgene expression in vivo.
An interesting observation from these experiments was that, although the viral dose was increased over a range of 2 × 10 6 -2 × 10 7 plaque-forming units (p.f.u.), levels of transgene product did not vary significantly in the recovered lavage fluids. This suggested that 2 × 10 6 infectious particles of the HSV vector might be a saturating dose in the rabbit knee joint. To determine if a dose-response curve could be generated, three-fold lower increments of T/0−TNFSR were injected into the knee joints of rabbits and TNFSR levels were measured in recovered lavage fluids. As shown in Figure 2c , while maximal gene expression was obtained using 2 × 10 6 p.f.u., significant TNFSR expression could be detected when as little as 2 × 10 5 p.f.u. were delivered into the joint, demonstrating that the T/0− based vector is highly infectious in the articular environment.
The results of the experiments in naive animal joints showed that the second-generation HSV vector permitted sustained intra-articular transgene expression following direct in vivo delivery. To determine if therapeutic levels of biologically active protein could be expressed within the joint following HSV T/0-mediated gene transfer, we evaluated the ability of this vector to inhibit the pathology associated with an experimental model of arthritis. While soluble TNF antagonists have shown therapeutic benefit in humans, recent experimental evidence in our laboratory has demonstrated only limited effects in rabbit models following intra-articular delivery. 12 We have previously demonstrated that delivery of the human IL-1␤ gene to the joints of rabbits via ex vivo transfer of retrovirally transduced HIG-82 cells was capable of inducing all major pathologies associated with RA in Figure 1 human patients. 21 In initial experiments, 10 7 IL-1␤ expressing cells were directly injected into the joints of rabbits. While lavage fluids recovered from these joints contained only 100 pg/ml of IL-1 this procedure resulted in a severe, highly aggressive arthritic state that was nearly fatal to the experimental animals. Further experiments have shown that intra-articular injection of lower numbers of HIG-82-IL-1␤ cells results in a proportionally less severe response. To evaluate the ability of the second generation HSV vector to deliver biologically relevant levels of a therapeutic protein using this model system, the TNFSR coding region was replaced by the coding sequence for human interleukin-1 receptor antagonist (IL-1Ra) (Figure 1) .
Schematic representation of the vectors used in this study. HSV genome is represented as the unique long and short regions (horizontal bars) and terminal repeat regions (open boxes). Solid vertical bars indicate inactivated HSV genes. Expanded regions show expression cassettes with arrows indicating the direction in which the
The ability of the T/0-IL-1Ra vector to deliver and express the IL-1Ra coding region was first tested in vitro. Following infection of HIG-82 cells at an MOI of 3, greater than 130 ng of IL-1Ra was produced by 10 6 cells in 24 h (Figure 3a) . To examine the effects of IL-1Ra expression in the model of arthritis driven exclusively by overexpression of IL-1␤ approximately 2 × 10 6 p.f.u. of the T/0-IL-1Ra virus were injected into one knee of six naive rabbits. A similar dose of the same HSV T/0− backbone encoding lacZ (TOZ.1) (Figure 1 ) was injected into the opposing knee joint of each animal. Twenty-four hours later, 2.5 × 10 4 HIG-82-IL-1␤ cells were injected into both knees of each animal. This procedure results in a mild inflammation of joints even though intra-articular hIL-1 levels are below the limits of detection (Ͻ3 pg/ml). At 5 days after injection of the IL-1␤ expressing cell line, the rabbits were killed and the knee joints lavaged, dissected and analyzed for any effects of transgene expression.
As shown in Figure 3b , a mean value of greater than 1200 pg/ml of IL-1Ra was measured in joints injected with the T/0-IL-1Ra vector, while only background levels were observed in opposing joints. As a quantitative index of inflammation in the rabbit knees, leukocytes in recovered lavage fluids were counted and compared. As shown in Figure 3c , knee joints receiving the T/0-IL-1Ra vector showed a mean, three-fold reduction in leukocytosis relative to joints injected with the TOZ.1 control vector. Histological examination of joint capsules recovered from each of the animals showed that knee joints receiving the IL-1Ra gene had a considerably less severe synovitis relative to the opposing joints receiving the lacZ gene (Figure 4 ). Although the synovium was somewhat thickened and infiltrated in the IL-1Ra+ knees relative to normal joints, the overall pathology of the joints injected with the T/0-IL-1Ra vector was noticeably less than that of knees receiving the TOZ.1 vector. The results of these experiments demonstrated that in vivo gene transfer using a second-generation HSV vector could permit sustained expression of a therapeutic protein at biologically relevant levels.
Discussion
The results reported here demonstrate that second-generation HSV vectors deficient for the immediate-early genes, ICP4, 22 and 27 show significantly prolonged transgene expression in vivo in rabbit knee joints relative 
or T/0-IL-1Ra vector (MOI 3). At 24 h after infection IL-1Ra levels in supernatants from each culture were measured by ELISA. (b and c) Opposing knee joints of six rabbits were injected with 2 × 10 6 p.f.u. of either HSV T/0-IL-1Ra (right knee) or TOZ.1 (left knee). Twenty-four hours later, approximately 2.5 × 10 4 HIG-82-IL-1␤ cells were injected into both knees of all animals. Five days later the rabbits were killed and the joints lavaged with saline. IL-1Ra content in recovered lavage fluids was measured by ELISA (b) and infiltrating leukocytes were counted using a hemocytometer (c). Differences in leukocytic infiltration observed in the right knee treated with T/0-IL-1Ra were significantly different from joints treated with TOZ.1 and untreated IL-1 positive controls (P Ͻ 0.05 by paired Student's t test).
to first-generation, ICP4 deficient vectors. While expression with the first-generation vector was found to be limited to 48 h or less, high levels of transgene expression could be detected for at least 7 days following intra-articular injection with the less cytotoxic, secondgeneration vector. Furthermore, the levels of transgene expression from the newer HSV vector in vivo are biologically relevant; as shown by the ability of vector-produced IL-1Ra to reduce the pathology associated with an IL-1␤-induced model of arthritis. The results of these experi-
Figure 4 Histological analysis of synovial tissue recovered from rabbit knees. Knee joints of rabbits from Figure 3 were dissected and the synovial tissue harvested, sectioned and stained with hematoxylin and eosin. Naive: synovium from a normal naive rabbit knee. Toz.1: synovial tissue recovered from rabbit knee receiving HSV TOZ.1. T/0-IL-1Ra: synovium recovered from opposing joint injected with HSV T/0-IL-1Ra.
ments demonstrate a significant advancement in the development of HSV vectors for use in gene therapy applications for the treatment of RA and other joint pathologies.
An interesting observation from these experiments is the lack of a dose-response when higher levels of the HSV T/0-vector were delivered to the joint. This would suggest that near-saturating levels of infection were achieved following injection of approximately 2 × 10 6 p.f.u. In previous experiments using adenoviral vectors, approximately 10-to 30-fold higher infectious particles were required to attain a similar level of transgene expression in vivo. Although the relative infectivity of these two viruses for synovial tissues has not been systematically compared, the data suggest that HSV may be substantially more infectious for articular tissues than adenovirus. This may be due to the fact that the synovial lining is very similar in nature to the mucosal membranes that HSV normally infects in a host. This high level of infectibility could be advantageous in future gene-delivery applications. We have found that intra-articular injection of preparations containing high numbers of viral particles, 10 10 or greater, into the joint space can provoke an immediate inflammatory response. If indeed a lower dose of HSV vector can be used to deliver a comparable level of transgene product than with an adenoviral vector, then the potential for an inflammatory reaction may be reduced.
In contrast to previous studies, we note that no evidence of a therapeutic effect was observed in joints contralateral to knees receiving the IL-1Ra gene. Since the underlying mechanism for the earlier observation remains unclear, it is impossible to attribute this difference to a specific cause with any certainty. However, distinct differences in the experimental strategies may contribute. In the previous study, adenoviral vectors were delivered to joints in acute stages of intense inflammation that were heavily infiltrated. It was found that a population of leukocytes could be transduced by the virus and migrate to the opposing arthritic joint. In experiments described here, the herpes simplex virus was injected into rabbits with uninflamed joints that were essentially devoid of infiltrating cells. That these cells may be important in distal transgene effects is further suggested by the observation that effects resulting from ex vivo delivery of genetically modified, rabbit synovial fibroblasts are localized to the joint of injection.
These studies suggest that second-generation HSV vectors represent a useful tool for delivery and short-term overexpression of transgenes within the joint. Thus, in the laboratory they may have applications in screening the therapeutic value of other genes with anti-arthritic potential. However, the expression profile from these vectors is still insufficient for a treatment strategy requiring persistent transgene expression. Furthermore, preliminary studies indicate that redosing of joints that have lost expression does not result in subsequent reexpression of the transgene from synovial cells. However, this lack of expression may be dependent on the transgene product and the cell type in which it is produced. Clearly, additional research is necessary, and further modifications will be required to HSV-based vectors before they can be considered practical for therapeutic strategies that are likely to require persistent gene expression, such as the delivery of anti-inflammatory proteins or cytokine antagonists. However, the limited expression profile from HSV T/0-based vectors may make them useful in other approaches to the treatment and study of RA. One such strategy would be to use these vectors to deliver either suicide genes, such as thymidine kinase and cytosine deaminase, or apoptosis-inducing genes such as Fas ligand, to the hypertrophied synovial lining in RA patients. Such a strategy could result in the targeted cell death of the aggressive synovial layer thereby reducing the synovial lining without surgery. Such an approach, while not curative in nature, might slow the destructive progression of RA and allow for extended use of afflicted joints.
Previous studies with adenovirus 12, 22 and work described here with herpes simplex virus have provided mounting evidence for the feasibility of using viral vectors directly to deliver and express genes encoding antiarthritic proteins locally, within the joint, at beneficial levels. It should be noted that the animal models in which these vector systems were tested, antigen-induced arthritis in rabbits and collagen-induced arthritis in mice, present models with severe articular pathologies with rapid and intense onset. The time-course of these models is not indicative of the slow progression of the RA disease process in humans. It is possible that successful genebased therapy for arthritis in humans may not require the excessively high levels of gene expression required to observe beneficial effects in animal models. Instead, it may be possible to alter the course of the disease by more subtle, but persistent, expression of an anti-inflammatory agent(s). Over time, a small increase in the intra-articular level of a protein, such as IL-1Ra, may be sufficient to realize a beneficial outcome in RA patients. This type of expression profile may also be of great benefit in the treatment of other joint diseases, such as osteoarthritis. Recent studies by Samaniego et al 23 have shown that inactivation of all immediate-early coding regions of the HSV virus, ICP4, 22, 27, 47 and 0, significantly increase the persistence of the HSV genome in infected cultures. However, transgene expression without the presence of ICP0 protein was found to be reduced considerably. This situation is similar to that observed with adenoviral vectors that are completely gutted of viral coding sequences. 24, 25 It may be that vector systems of this type, with improved persistence at the expense of levels of expression, may prove beneficial in treating human disease without evidence of therapeutic efficacy in acute, rapidly progressing animal models.
Recent experiments in our laboratories have suggested that intra-articular delivery of HSV-based vectors may provide substantial gene delivery to neurons innervating the joint (Wolfe and Glorioso, unpublished). These infected neurons appear to provide a repository for transgene production in the infected joint when a neuron-specific long-term promoter is utilized. When transcription is driven by the viral latency active promoter LAP2, we have observed expression of nerve growth factor (NGF) in the mouse trigeminal ganglia the rat dorsal root ganglia and the rabbit knee joint, continued undiminished for many months. This type of expression profile was not observed in experiments described here, involving the transfer of TNFSR and IL-1Ra cDNAs. Since protein processing and secretion from neuronal cells differs from other cell types, it is possible that the effective release of exogenous transgene products from neurons may require the substitution of their natural secretory signal sequences with a leader polypeptide from a protein normally secreted from neurons, such as NGF. We are currently testing this hypothesis by creating such chimeric anti-inflammatory proteins for secretion from neurons innervating the rabbit knee joint for use in arthritis models.
Materials and methods

Plasmid and vector construction
Plasmid p41ICP0-sTNFR: To facilitate the insertion of the TNFSR expression cassette into the HSV genome, a recombination plasmid, p41ICP0-sTNFR, in which the TNFSR coding sequence is under transcriptional control of the HSV ICP0 promoter was created. This plasmid was generated by modifying the previously described plasmid p41ICP0lacZ 26 such that the lacZ sequences were removed and replaced with the TNFSR type I receptor cDNA fused to the mouse IgG1 domain and the SV40 polyadenylation sequence. 27 This was accomplished by digesting p41ICP0lacZ with PacI (PacI sites flank the lacZ coding sequence) and blunting the ends with Klenow in the presence of dNTPs. Subsequently, the TNFSR sequences were inserted as a blunt fragment and clones with the insert in the correct orientation identified by restriction digestion. The resulting plasmid contains the TNFSR cDNA expression cassette flanked by sequences from the HSV UL41 locus (5′ Flank: 93858-92194; 3′ Flank 91606-90145).
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Plasmid P41ICPO-IL-1Ra: This plasmid was constructed in the same manner as p41ICP0-TNFSRexcept that the IL1Ra cDNA fused to the SV40 polyadenylation sequence was inserted into p41ICP0lacZ in place of the TNFSR cDNA. 3 Vectors S/0-TNFSR and T/0-sTNF␣R: The TNFSR recombination plasmid described above was introduced into the genome of SOZ.1 using the previously described PacI recombination strategy. 26 Briefly, PacI endonuclease digested SOZ.1 genomic DNA was co-transfected along with the recombination plasmid p41ICP0-TNFSRinto 7b cells using standard calcium phosphate methods. This cell line provides in trans, the HSV ICP4 and ICP27 immediate-early gene products that are essential for viral replication. Progeny viruses isolated from this transfection were screened for the presence of the expression cassette by Southern analysis. Positive isolates were purified by three rounds of limiting dilution, and expression of p55 (sTNFR) protein was confirmed by ELISA measurements of culture supernatants. The resultant, ICP4 deficient, vector was named S/0−sTNFR. To generate a TNFSR vector in the less toxic ICP4, 22, 27 deficient, vector backbone, S/0−TNFSR was genetically crossed with the ICP4, 22, 27 deficient vector TOZ.1 by infecting 7b cells with both vectors at an MOI of 5. Progeny virus isolated were screened for p55 expression as well as the ICP27 and ICP22 genomic deletions. A TNFSR positive ICP4, ICP22, ICP27 deficient virus was identified and named T/0− TNFSR. Vector T/0−IL-1Ra was created in exactly the same manner as T/0− TNFSR except that P41ICPO-IL-1RA was used in place of the TNFSR recombination plasmid.
Vector stocks were prepared by infecting 3 × 10 8 7b cells at an MOI of 0.03 and harvesting virus when infec-tion was complete (approximately 48 h after infection). At this point infected cells were harvested by scraping and pelleted by centrifugation at 5000 g, for 10 min. The cell pellet was processed while the cleared media were stored on ice. Virus was released from the cell pellet by three rounds of freezing and thawing followed by sonication at 20 W for 30 s. Cell lysates were then cleared by centrifugation at 10 000 g for 10 min and combined with the previously cleared media. Virus was recovered from the media and cell lysates by centrifugation at 20 000 g for 1 h, and purified by banding on a nycodenz gradient. The recovered virus was diluted in 30 ml cold PBS and repelleted. The final pellet was resuspended in cold PBS, divided into aliquots and stored at −80°C.
To determine IL-1Ra and TNFSR levels produced from the vectors in vitro, 1 × 10 6 HIG-82 cells were infected with each vector at an MOI of 3, in triplicate. At 24 h after infection, culture supernatants were harvested, and IL-1Ra and TNFSR production were quantified using commercially available ELISA kits (R&D Systems, Minneapolis, MN, USA).
Animal models and biological assays
A retroviral vector, DFG-hIL-1␤-neo encoding both the mature form of human IL-1␤ fused to the secretory polypeptide sequence from human parathyroid hormone, and the neomycin phosphotransferase genes was used to transduce HIG-82 cells. Following infection, transduced cells were positively selected by culture in DMEM containing 10% FBS and 0.5 mg/ml G418. After selection, this cell line was found to produce over 200 ng of IL-1␤ per 10 6 cells per 48 h. To induce arthritis in the rabbit knee, the HIG-82-IL-1␤+ cells were first trypsinized from culture plates, washed twice in Gey's balanced salts solution (GBSS) and counted using a hemocytometer. Approximately 2.5 × 10 4 of the cells were resuspended in GBSS in a 0.25 ml volume and injected via the parapatellar approach into both knees of 3-4 g New Zealand White rabbits. In order to monitor intra-articular transgene expression and WBC infiltrate rabbit joints were lavaged by direct intra-articular injection of 1 ml GBSS; the joints were flexed and extended several times, the lavage fluid aspirated, aliquoted and stored at −80°C. Rabbits were killed by intravenous overdose of Nembutal via the ear vein. Following death, joint capsules were dissected from the knees, fixed in 10% formalin and paraffin embedded. Five m sections were stained with hematoxylin and eosin using standard methods. ELISA measurements of human IL-1Ra and TNFSR in lavage fluids were performed as directed using a commercially available kit from R&D Systems.
